Acadian Asset Management LLC Aravive, Inc. Transaction History

Acadian Asset Management LLC

$32.5 Billion
Q2 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.0 - $0.13 $0 - $403	-3,100 Reduced 0.18%	1,758,982 $69,000
Q4 2023 Feb 13, 2024	SELL	$0.11 - $0.22 $26,957 - $53,915	-245,072 Reduced 12.21%	1,762,082 $216,000
Q3 2023 Nov 13, 2023	BUY	$0.11 - $1.76 $220,786 - $3.53 Million	2,007,154 New	2,007,154 $263,000
Q4 2022 Feb 14, 2023	SELL	$1.2 - $1.83 $120,745 - $184,136	-100,621 Reduced 86.48%	15,729 $20,000
Q2 2022 Aug 09, 2022	SELL	$0.93 - $1.9 $2 - $5	-3 Reduced -0.0%	116,350 $115,000
Q1 2022 May 12, 2022	BUY	$1.85 - $2.75 $13,290 - $19,756	7,184 Added 6.58%	116,353 $223,000
Q4 2021 Feb 10, 2022	BUY	$2.19 - $4.07 $119,996 - $223,007	54,793 Added 100.77%	109,169 $238,000
Q3 2021 Nov 12, 2021	BUY	$3.67 - $5.8 $67,663 - $106,934	18,437 Added 51.3%	54,376 $202,000
Q2 2021 Aug 11, 2021	BUY	$4.65 - $6.42 $62,328 - $86,053	13,404 Added 59.48%	35,939 $214,000
Q1 2021 May 11, 2021	BUY	$5.11 - $9.24 $115,153 - $208,223	22,535 New	22,535 $149,000
Q4 2020 Feb 11, 2021	SELL	$4.36 - $6.51 $119,102 - $177,833	-27,317 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$4.7 - $12.06 $128,389 - $329,443	27,317 New	27,317 $128,000
Q2 2020 Aug 12, 2020	SELL	$5.18 - $14.81 $29,101 - $83,202	-5,618 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$3.5 - $13.77 $19,663 - $77,359	5,618 New	5,618 $32,000
Q4 2019 Feb 06, 2020	SELL	$6.21 - $14.02 $33,962 - $76,675	-5,469 Closed	0 $0
Q2 2019 Aug 08, 2019	SELL	$5.65 - $7.5 $21,905 - $29,077	-3,877 Reduced 41.48%	5,469 $33,000
Q1 2019 May 09, 2019	SELL	$3.35 - $8.27 $25,557 - $63,091	-7,629 Reduced 44.94%	9,346 $65,000
Q4 2018 Feb 07, 2019	BUY	$3.23 - $8.7 $54,829 - $147,682	16,975 New	16,975 $60,000

Others Institutions Holding ARAV

# of Institutions

Shares Held

28.1K

Call Options Held

Put Options Held

View Full List

About Aravive, Inc.

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

More about ARAV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account